Cyclopharm Limited
ASX:CYC.AX
1.565 (AUD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) AUD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 27.14 | 23.219 | 17.705 | 14.676 | 14.079 | 13.404 | 13.189 | 14.386 | 12.583 | 12.047 | 11.882 | 10.744 | 10.315 | 9.465 | 13.112 | 10.888 | 11.128 |
| Cost of Revenue
| 22.642 | 17.279 | 14.502 | 12.596 | 9.213 | 7.76 | 6.836 | 7.239 | 6.121 | 3.427 | 3.508 | 3.349 | 3.128 | 2.309 | 2.546 | 2.532 | 3.122 |
| Gross Profit
| 4.497 | 5.94 | 3.203 | 2.08 | 4.866 | 5.645 | 6.353 | 7.146 | 6.462 | 8.62 | 8.374 | 7.395 | 7.187 | 7.156 | 10.566 | 8.357 | 8.006 |
| Gross Profit Ratio
| 0.166 | 0.256 | 0.181 | 0.142 | 0.346 | 0.421 | 0.482 | 0.497 | 0.514 | 0.716 | 0.705 | 0.688 | 0.697 | 0.756 | 0.806 | 0.767 | 0.719 |
| Reseach & Development Expenses
| 3.689 | 3.44 | 1.66 | 3.538 | 4.193 | 3.219 | 2.871 | 1.157 | 0.727 | 0.014 | 0.038 | 0.023 | 0 | 0.017 | 0.04 | 0.036 | 0.029 |
| General & Administrative Expenses
| 13.999 | 10.965 | 10.793 | 9.47 | 6.376 | 5.569 | 5.382 | 5.099 | 3.994 | 4.273 | 4.779 | 4.436 | 3.454 | 4.077 | 4.832 | 5.111 | 5.377 |
| Selling & Marketing Expenses
| 2.049 | 2.924 | 1.022 | 0.846 | 0.645 | 0.755 | 0.802 | 0.75 | 0.792 | 0.777 | 0.938 | 0.931 | 0.584 | 0.581 | 0.656 | 0.652 | 0.66 |
| SG&A
| 9.692 | 9.78 | 7.977 | 6.625 | 6.565 | 4.965 | 4.83 | 3.966 | 3.158 | 5.051 | 5.717 | 5.367 | 4.038 | 4.659 | 5.488 | 5.763 | 6.037 |
| Other Expenses
| 5.562 | 1.76 | 2.691 | 2.846 | 4.095 | 2.487 | 2.367 | -0.018 | 1.974 | 2.414 | 0.141 | -0.203 | -0.207 | 1.231 | 0.482 | 0.049 | 0.101 |
| Operating Expenses
| 13.381 | 13.22 | 9.637 | 10.162 | 10.757 | 8.184 | 7.701 | 5.123 | 3.885 | 7.536 | 8.933 | 7.843 | 7.458 | 5.907 | 7.652 | 6.256 | 6.494 |
| Operating Income
| -8.884 | -7.28 | -6.434 | -8.083 | -5.891 | -2.54 | -1.349 | 2.023 | 2.577 | 3.578 | -0.656 | -0.627 | -0.837 | 1.007 | 3.397 | 2.15 | 1.613 |
| Operating Income Ratio
| -0.327 | -0.314 | -0.363 | -0.551 | -0.418 | -0.189 | -0.102 | 0.141 | 0.205 | 0.297 | -0.055 | -0.058 | -0.081 | 0.106 | 0.259 | 0.198 | 0.145 |
| Total Other Income Expenses Net
| 4.694 | -0.386 | -0.204 | -0.766 | 0.532 | 0.536 | -0.337 | -0.602 | 1.513 | 2.474 | -0.112 | -0.203 | -0.583 | -0.311 | -0.209 | 0.049 | 0.101 |
| Income Before Tax
| -4.19 | -7.666 | -6.638 | -8.849 | -5.359 | -2.004 | -1.685 | 1.421 | 4.09 | 3.47 | -0.926 | -1.011 | -1.192 | 0.808 | 2.568 | 1.896 | 1.39 |
| Income Before Tax Ratio
| -0.154 | -0.33 | -0.375 | -0.603 | -0.381 | -0.15 | -0.128 | 0.099 | 0.325 | 0.288 | -0.078 | -0.094 | -0.116 | 0.085 | 0.196 | 0.174 | 0.125 |
| Income Tax Expense
| 0.511 | -1.054 | -1.598 | -2.805 | -2.447 | -1.968 | -0.161 | 0.53 | -0.703 | -0.595 | -0.146 | 0.033 | -0.236 | 0.358 | 0.523 | 0.139 | 0.258 |
| Net Income
| -4.701 | -6.612 | -5.04 | -6.044 | -2.912 | -0.035 | -1.525 | 0.891 | 4.793 | 4.066 | -0.78 | -1.044 | -0.956 | 0.45 | 2.044 | 1.757 | 1.131 |
| Net Income Ratio
| -0.173 | -0.285 | -0.285 | -0.412 | -0.207 | -0.003 | -0.116 | 0.062 | 0.381 | 0.337 | -0.066 | -0.097 | -0.093 | 0.048 | 0.156 | 0.161 | 0.102 |
| EPS
| -0.051 | -0.072 | -0.056 | -0.079 | -0.043 | -0.001 | -0.023 | 0.015 | 0.085 | 0.07 | -0.013 | -0.009 | -0.027 | 0.012 | 0.056 | 0.058 | 0.039 |
| EPS Diluted
| -0.051 | -0.072 | -0.056 | -0.079 | -0.043 | -0.001 | -0.023 | 0.015 | 0.083 | 0.07 | -0.013 | -0.009 | -0.027 | 0.012 | 0.056 | 0.058 | 0.039 |
| EBITDA
| -7.945 | -6.348 | -5.676 | -7.172 | -4.891 | -2.029 | -1.031 | 2.129 | 2.721 | 3.843 | -0.013 | 0.025 | -0.167 | 1.357 | 3.847 | 2.482 | 1.929 |
| EBITDA Ratio
| -0.293 | -0.273 | -0.321 | -0.489 | -0.347 | -0.151 | -0.078 | 0.148 | 0.216 | 0.319 | -0.001 | 0.002 | -0.016 | 0.143 | 0.293 | 0.228 | 0.173 |